PARSIPPANY, N.J., July 15, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal ® ODT. Actavis intends to launch the product immediately.
As a "first applicant" to submit a substantially complete ANDA, Actavis may be eligible for 180 days of generic market exclusivity. While the Company failed to obtain tentative approval of its ANDA within 40 months after the date on which it was filed, the FDA is not making a formal determination on Actavis' eligibility for 180-day exclusivity at this time. It will do so only if another paragraph IV applicant becomes eligible for full approval within 180 days after Actavis begins commercial marketing of its product.
Lamictal ® ODT is an antiepileptic drug indicated for the treatment of epilepsy and bipolar disorder. For the 12 months ending May 31, 2013, Lamictal ® ODT had total U.S. sales of approximately $51 million, according to IMS Health data.
About ActavisActavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Parsippany, New Jersey, USA. Operating as Actavis Pharma, Actavis develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical business focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts